Psyence Biomedical updates 2023 equity incentive plan

Psyence Biomedical Ltd. filed a Form 6-K as a foreign private issuer to report a technical change to its 2023 Equity Incentive Plan.

Rhea-AI Filing Summary

Psyence Biomedical Ltd. filed a Form 6-K as a foreign private issuer to report a technical change to its 2023 Equity Incentive Plan. On May 4, 2026, the board approved an amendment and restatement of the plan to correct a typographical error in Section 4(b).

The updated plan, referred to as the First Amended and Restated Equity Incentive Plan, is provided in full as Exhibit 10.1. The filing does not describe any change to plan substance beyond this correction and is signed by the company’s Chief Financial Officer, Warwick Corden-Lloyd.

Key Terms

foreign private issuer, 2023 Equity Incentive Plan, amended and restated, First Amended and Restated Plan, +1 more

5 terms

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

2023 Equity Incentive Plan financial

"to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan"

amended and restated regulatory

"approved a resolution to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan"

First Amended and Restated Plan financial

"description of the amended and restated Plan (the “First Amended and Restated Plan”)"

Exhibit 10.1 regulatory

"furnished as Exhibit 10.1 hereto and incorporated herein by reference"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Psyence Biomedical (PBM) change in its 2023 Equity Incentive Plan?

Psyence Biomedical corrected a typographical error in Section 4(b) of its 2023 Equity Incentive Plan. The board approved an amended and restated version, called the First Amended and Restated Equity Incentive Plan, which is provided in full as Exhibit 10.1 to the Form 6-K.

When did Psyence Biomedical (PBM) approve the amendment to its equity plan?

The board of Psyence Biomedical approved the amendment and restatement of its 2023 Equity Incentive Plan on May 4, 2026. This action is reported in a Form 6-K for June 2026 and formally documented through the First Amended and Restated Equity Incentive Plan.

Where can investors see the full text of Psyence Biomedical’s amended 2023 equity plan?

The complete First Amended and Restated Equity Incentive Plan is included as Exhibit 10.1 to the Form 6-K. The filing states that the brief description is qualified in its entirety by reference to this full exhibit, which contains the detailed plan terms.

Does Psyence Biomedical’s Form 6-K describe major changes to compensation or just a correction?

The Form 6-K explains that the 2023 Equity Incentive Plan was amended and restated to correct a typographical error in Section 4(b). It characterizes this as a corrective update, without describing broader or substantive changes to the plan’s overall structure or purpose.

Who signed Psyence Biomedical’s June 2026 Form 6-K related to the equity plan?

The Form 6-K was signed on behalf of Psyence Biomedical by Warwick Corden-Lloyd, the company’s Chief Financial Officer. The signature section confirms the filing was duly authorized, with the document dated June 5, 2026 under the Securities Exchange Act of 1934.

What type of SEC filer is Psyence Biomedical (PBM) in this submission?

Psyence Biomedical submitted this report as a foreign private issuer on Form 6-K under Rules 13a-16 or 15d-16. The filing covers the month of June 2026 and reports the technical amendment to the company’s 2023 Equity Incentive Plan approved in May 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:16 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-41937

Psyence Biomedical Ltd.

(Translation of registrant’s name into English)

121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F     ☐ Form 40-F 

EXPLANATORY NOTE

On May 4, 2026, the board of directors (the “Board”) of Psyence Biomedical Ltd. (the “Company”) approved a resolution to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan (the “Plan”) to correct a typographical error in Section 4(b).

The foregoing description of the amended and restated Plan (the “First Amended and Restated Plan”) does not purport to be complete and is qualified in its entirety by reference to the full text of the First Amended and Restated Plan, which is furnished as Exhibit 10.1 hereto and incorporated herein by reference.

1

EXHIBIT INDEX

Exhibit No.		Description
10.1		Psyence Biomedical Ltd. 2023 First Amended and Restated Equity Incentive Plan.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 5, 2026

Psyence Biomedical Ltd.
By:	/s/ Warwick Corden-Lloyd
Name:	Warwick Corden-Lloyd
Title:	Chief Financial Officer

3

Filing Exhibits & Attachments

1 document

Agreements & Contracts

• EX-10.1 PSYENCE BIOMEDICAL LTD. 2023 FIRST AMENDED AND RESTATED EQUITY INCENTIVE PLAN 156.6 KB